DKSH, the leading Market Expansion Services Group with a focus on Asia, helped Japanese pharmaceutical company Taiho Pharmaceutical Co., Ltd. to receive market authorization for its TS-ONE product in Hong Kong.
HONG KONG, April 12, 2012 /PRNewswire-Asia/ -- DKSH's Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, has successfully helped Taiho Pharmaceutical register its oral agent products in Hong Kong. Taiho's oral fluoropyrimidine product TS-ONE, has received marketing authorization in Hong Kong for both 20mg and 25mg capsules. The productdeveloped by Taiho, is already available in Asian countries, which are Japan, South Korea, mainland China, Singapore and Taiwan.
TS-ONE has been approved in Hong Kong and will be distributed and marketed by DKSH.
"We selected DKSH as our regional partner and chose them to register TS-ONE in Hong Kong due to their strong expertise and deep experience in registration of healthcare products, their extensive market knowledge, as well as their direct capillary distribution network throughout Asia," said Junichi Saruta, Global Business Managing Director of Taiho.
"Taiho is an important long-term regional partner for us and we are proud to help them grow their business with our Market Expansion Services in several countries," said Kentaro Imamoto, Business Development Director for Japanese clients, DKSH Healthcare. "With the registration of TS-ONE in Hong Kong, we have once again proven our ability to smoothly register our clients' products in new markets and pave the way for successful market entrances," he added.
About DKSH
DKSH is the leading Market Expansion Services Group with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets.
With 650 business locations in 35 countries -- 630 of them in Asia -- and over 24,000 specialized staff, it is one of the top 20 Swiss companies ranked by sales and employees. In 2011, DKSH generated Net Sales of CHF 7.3 billion.
DKSH's Business Unit Healthcare is a leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health, and medical device companies. The Business Unit provides a comprehensive portfolio of integrated services ranging from product registration, importation, manufacturing, marketing and sales to distribution, and after-sales.
With 150 business locations in 13 countries and over 8,000 specialized staff, Business Unit Healthcare generated Net Sales of CHF 2.9 billion in 2011.
About Taiho Pharmaceutical Co. Ltd.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma company focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to the enrichment of society." In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing evidence-based medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, please visit http://www.taiho.co.jp/english/.
